Live Feeds
● TRACKER Updated 28d ago · 6 sources tracked

The Surprising Reason This Biotech Just Plummeted 71%

EyePoint shares dropped between 69% and 71% following the failure of a late-stage clinical trial for DURAVYU 2.7mg. The drug targets wet age-related macular degeneration (AMD). The company released topline data from LUGANO, the first of two pivotal Phase 3 trials. While the results disappointed investors and caused a stock spiral, EyePoint maintains that the treatment still shows promise. The failure occurs during a competitive race to develop next-generation treatments for AMD.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (6)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ EyePoint shares fell between 69% and 71% following the trial results.
  • ✓ The LUGANO trial was the first of two pivotal Phase 3 clinical trials for DURAVYU 2.7mg in wet AMD.
  • ✓ The late-stage trial for the age-related eye disease drug failed.
🛡️ Source Corroboration: 6 independent reporting domains (95% confidence) ⏱ Read time: ~2 min

What changed

EyePoint announced topline data from its LUGANO Phase 3 clinical trial showing the DURAVYU 2.7mg treatment failed.

Live updates

  1. EyePoint Shares Plummet After Phase 3 Trial Failure for Wet AMD Drug

    EyePoint shares dropped between 69% and 71% following the failure of a late-stage clinical trial for DURAVYU 2.7mg. The drug targets wet age-related macular degeneration (AMD). The company released topline data from LUGANO, the first of two pivotal Phase 3 trials. While the results disappointed investors and caused a stock spiral, EyePoint maintains that the treatment still shows promise. The failure occurs during a competitive race to develop next-generation treatments for AMD.

    Why it matters

    Wet AMD is a leading cause of vision loss in older adults. EyePoint is competing in a high-stakes biotech race to create more effective or convenient delivery methods for vision treatments. The outcome of pivotal Phase 3 trials typically determines whether a drug receives regulatory approval for market sale.

    What is confirmed

    • EyePoint shares fell between 69% and 71% following the trial results.
    • The LUGANO trial was the first of two pivotal Phase 3 clinical trials for DURAVYU 2.7mg in wet AMD.
    • The late-stage trial for the age-related eye disease drug failed.

    Still unconfirmed

    • The market reaction to the trial failure may be an overreaction.

    What to watch next

    • Results from the second pivotal Phase 3 clinical trial for DURAVYU 2.7mg
    • Further guidance from EyePoint regarding the promise of the vision treatment
    Sources used for this update (6)
    1. Investor's Business Daily — The Surprising Reason This Biotech Just Plummeted 71%
    2. Barron's — EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.
    3. BioSpace — EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
    4. Reuters — EyePoint's drug for age-related eye disease fails late-stage trial, shares tank
    5. STAT — Eyepoint study results for vision treatment disappoint, but company still sees promise
    6. Yahoo Finance — EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
    confidence 95%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community